The Patient Protection and Affordable Care Act, commonly known as Obamacare, is undoubtedly the most hotly debated topic in the health-care sector today. The ultimate impact of the law on many health-care stocks remains unclear, but there is one obscure group of companies -- called contract research organizations, or CROs -- that are largely insulated from the Obamacare debate and are also profiting from big pharma outsourcing.
In the video below, analysts Michael Olsen and Max Macaluso discuss CROs, including Parexel International (PRXL), Quintiles Transnational Holdings (IQV 1.73%), Covance, and Icon (ICLR 0.43%), and why investors should take notice of this industry today.
